# ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases

> **NCT02048059** · PHASE2 · COMPLETED · sponsor: **Angiochem Inc** · enrollment: 72 (actual)

## Conditions studied

- Breast Cancer
- Brain Metastases

## Interventions

- **DRUG:** ANG1005

## Key facts

- **NCT ID:** NCT02048059
- **Lead sponsor:** Angiochem Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04
- **Primary completion:** 2016-03
- **Final completion:** 2017-09
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2020-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02048059

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02048059, "ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT02048059. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*